Invivyd, Inc. (NASDAQ:IVVD - Free Report) - Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for Invivyd in a research note issued to investors on Tuesday, May 14th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn $0.02 per share for the quarter, down from their previous forecast of $0.05. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Invivyd's current full-year earnings is ($0.65) per share.
IVVD has been the subject of several other reports. Guggenheim raised Invivyd from a "neutral" rating to a "buy" rating and set a $9.00 target price for the company in a research report on Friday, April 5th. Morgan Stanley raised Invivyd from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $4.00 to $10.00 in a research report on Tuesday, March 26th.
Get Our Latest Research Report on IVVD
Invivyd Price Performance
NASDAQ IVVD traded up $0.03 on Wednesday, reaching $2.46. The company had a trading volume of 451,338 shares, compared to its average volume of 772,823. The firm has a market cap of $293.53 million, a price-to-earnings ratio of -1.30 and a beta of 0.89. Invivyd has a fifty-two week low of $0.98 and a fifty-two week high of $5.20. The business has a 50 day moving average of $3.05 and a two-hundred day moving average of $3.14.
Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings results on Thursday, March 28th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.26).
Institutional Investors Weigh In On Invivyd
Several institutional investors and hedge funds have recently made changes to their positions in IVVD. Acadian Asset Management LLC bought a new position in shares of Invivyd during the 1st quarter worth approximately $905,000. Vanguard Group Inc. lifted its position in shares of Invivyd by 3.9% during the 1st quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company's stock valued at $11,594,000 after acquiring an additional 97,496 shares during the period. SG Americas Securities LLC bought a new position in Invivyd during the first quarter worth $56,000. Chase Investment Counsel Corp bought a new position in Invivyd during the first quarter worth $271,000. Finally, a16z Perennial Management L.P. bought a new stake in Invivyd in the fourth quarter valued at $315,000. Institutional investors own 70.36% of the company's stock.
Invivyd Company Profile
(
Get Free Report)
Invivyd, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is adintrevimab, a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease, as well as developing monoclonal antibody candidates, including VYD222 and VYD224, which provides neutralizing protection against SARS-CoV-2.
See Also
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
